Sanofi’s latest bet on a potential Dupixent sequel is a preclinical pill developed by a British small-cap that specializes in virtual reality chemistry.
The French pharma rolled the dice Monday on an up to $500 million deal with C4X Discovery. The milestone-heavy, $8 million upfront agreement will license to Sanofi a small molecule the discovery biotech developed to block the cytokine IL-17 — a potential oral treatment for psoriasis and other inflammatory conditions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,